Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 14, 2018

SELL
$5.07 - $7.92 $112,903 - $176,370
-22,269 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$5.4 - $8.47 $120,252 - $188,618
22,269
22,269 $170,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Qcm Cayman, Ltd. Portfolio

Follow Qcm Cayman, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qcm Cayman, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Qcm Cayman, Ltd. with notifications on news.